Medpace Holdings, Inc. (MEDP) closed at $389.41 on the recent trading session, showing a gain of 0.79% from the previous day’s price. This performance outpaced the S&P 500’s gain of 0.11%, while the Dow dropped 0.3% and the Nasdaq rose 0.56%. Over the past month, MEDP has decreased by 1.59%, underperforming the Medical sector’s increase of 2.86% and the S&P 500’s rise of 5.06%.
Upcoming financial results for Medpace are eagerly anticipated, with earnings per share (EPS) expected to be $2.52, a 30.57% increase year-over-year, and projected revenue of $529.73 million, up 14.94% from the same quarter last year. For the full year, consensus estimates forecast EPS of $11.29 and revenue of $2.17 billion, representing increases of 27.14% and 14.92% respectively. Medpace currently holds a Zacks Rank of #1 (Strong Buy), indicating positive analyst revisions.
As of the latest market data, Medpace has a Forward P/E ratio of 34.24, considerably higher than the industry average of 19.34. The company’s PEG ratio stands at 1.91, compared to the Medical Services industry’s average PEG of 1.57. The Medical Services sector ranks in the top 39% of industries based on Zacks Industry Rank.
